Source comparison
Complete Reference Table: Every Compound in the Comparison
One row per compound, with the receptor it actually binds. Somatropin (hGH) Recombinant hormone GH receptor (JAK2/STAT5) Subcutaneous Approved, specific indications only GH deficiency, Turner syndrome, HIV wasting, short bowel Sermorelin GHRH analogue (GHRH 1-
This comparison does not assign a generated winner or score.
- One row per compound, with the receptor it actually binds.
- Somatropin (hGH)
- Recombinant hormone
- GH receptor (JAK2/STAT5)
- Subcutaneous
- Approved, specific indications only
- GH deficiency, Turner syndrome, HIV wasting, short bowel
- Sermorelin
- GHRH analogue (GHRH 1-29)
- GHRH receptor
- Approval withdrawn 2009; compounded only
- Adult GH optimization, off-label
- Mod GRF 1-29 (CJC-1295 no DAC)
- GHRH analogue, stabilized
- Not approved
- Research; short-acting GHRH pulse
- CJC-1295 with DAC
- GHRH analogue + albumin tether
- Research; 5.8-8.1 day half-life
- Tesamorelin
- Approved (Egrifta), HIV lipodystrophy only
- Visceral adipose reduction
- Ipamorelin
- Ghrelin agonist (pentapeptide)
- GHS-R1a
- Research; selective, no cortisol rise
- GHRP-2
- Ghrelin agonist
- Research; modest prolactin/cortisol rise
- GHRP-6
- Research; strong hunger stimulus
- Hexarelin
- Research; desensitizes with repeat dosing
- MK-677 (ibutamoren)
- Non-peptide small molecule
- Oral
- Research; 24-hour IGF-1 elevation
- HGH Fragment 176-191
- GH C-terminal fragment
- No GH receptor activity
- Marketed for fat loss; releases no GH
- HGH Fragment 176-191 sits at the bottom because it is the compound most often filed under "HGH peptides" while doing none of the things on this page. It is a fragment of the growth hormone molecule with no GH-releasing action and no GH receptor agonism, marketed on lipolysis claims. Dose it with the HGH fragment dosage calculator if you use it, and do not expect an IGF-1 response.